YOLFTbeta
19

TegoScience Inc

191420 · KQ · Healthcare / Pharmaceuticals

6,530.00KRW-110.00 (-1.66%)

Price History

Full chart

Market Stats

Previous Close6,640.00
Open6,640.00
Day Range6,490.00 – 7,030.00
52-Week Range5,230.00 – 18,800.00
Volume1.17K
Market Cap57.33B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.14
50-Day Avg7,215.80
200-Day Avg10,776.75

About

TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEODr. Saewha Jeon Ph.D.
  • Employees0
  • Headquarters93, Magokjungang 8-ro, Seoul, South Korea, Korea
  • Websitehttp://www.tegoscience.com

Leadership

  • Dr. Saewha Jeon Ph.D.Co-Founder, Chief Exec. Officer and Chief Technology Officer
  • Mr. Jaewook JeonCo-Founder and Chief Strategy Officer
  • Mr. Yun Shim ChungSr. VP of Fin.
  • Mr. Min Young ChouVP of Admin.

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.49B8.34B8.64B7.85B6.35B8.79B8.30B7.68B7.77B6.76B5.94B
Growth (%)-+11.36%+3.59%-9.16%-19.16%+38.50%-5.57%-7.49%+1.22%-13.04%-12.11%
Cost of Revenue1.45B1.57B1.76B1.87B1.63B2.15B1.90B2.06B2.47B1.98B1.90B
Gross Profit6.04B6.77B6.88B5.98B4.72B6.64B6.40B5.61B5.30B4.78B4.04B
Gross Margin80.63%81.17%79.66%76.22%74.30%75.54%77.14%73.12%68.24%70.67%67.93%
Operating Expense4.67B4.59B5.00B5.11B4.37B5.06B6.50B5.40B7.63B7.01B8.46B
Operating Income1.37B2.19B1.88B872.81M345.96M1.58B-98.01M209.63M-2.33B-2.23B-4.42B
Operating Margin18.26%26.21%21.81%11.12%5.45%17.92%-1.18%2.73%-29.98%-33.00%-74.48%
EBITDA-------818.47M-1.95B3.47B-6.31B
EBITDA Margin-------10.66%-25.13%51.31%-106.14%
Net Income1.47B771.74M-6.02B-1.83B855.58M1.85B139.26M264.51M-2.32B3.35B-7.01B
Net Income Margin19.67%9.25%-69.67%-23.26%13.48%21.07%1.68%3.44%-29.88%49.56%-118.04%
R&D1.60B1.43B1.57B1.74B1.73B1.85B2.33B1.61B2.58B2.66B5.06B
R&D as % of Total Revenue21.42%17.17%18.15%22.20%27.30%21.07%28.05%20.94%33.14%39.40%85.26%
Interest Expense00007.44M7.96M16.53M35.48M62.39M89.77M1.25B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.12%0.09%0.20%0.46%0.80%1.33%21.07%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.76B44.64B47.59B47.56B48.57B50.40B51.00B51.36B48.91B52.52B78.16B
Total Liabilities551.82M18.66B11.87B882.02M750.71M1.41B2.53B2.77B2.58B2.66B27.83B
Total Equity25.21B25.98B35.71B46.68B47.82B48.99B48.47B48.60B46.46B49.86B50.51B
Cash854.08M4.19B429.10M1.26B1.63B1.61B2.61B807.89M2.11B1.60B12.64B
Total Debt-29.86B4.03B-31.59M44.54M-----
Net Debt-------292.11M--3.36B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.63B2.36B2.87B833.88M41.40M1.28B457.25M1.04B-794.61M-1.16B-3.07B
Investing Cash Flow-2.04B-15.22B-6.63B42.07M76.39M-1.26B-965.88M-2.99B2.00B587.89M-
Financing Cash Flow-145.02M16.20B-46.45M-46.45M254.45M-38.47M1.51B147.95M156.57M24.40M-
Capital Expenditure4.45B2.64B10.34B916.72M60.18M65.18M16.19M435.55M1.89B323.40M500.33M
Free Cash Flow----75.66M981.54M233.75M604.78M-2.68B-1.48B-3.57B
Dividends Paid185.02M----------
FCF to OCF----182.73%76.71%51.12%58.13%337.86%127.89%116.31%

Earnings

Report DateMay 16, 2015Aug 14, 2015Nov 13, 2015Mar 15, 2016May 12, 2016Aug 22, 2016Nov 13, 2016Feb 6, 2017May 14, 2017Aug 25, 2017Nov 26, 2017Feb 12, 2018May 25, 2018Aug 14, 2018Nov 14, 2018Feb 12, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 12, 2020May 12, 2020Aug 5, 2020Nov 5, 2020Feb 8, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------
EPS Actual12.8354.7093.1138.3137.3979.1393.95-106.2637.96-377.4842.58-539.5050.4726.3916.52-319.24-20.2857.6826.9041.7231.3566.0079.0052.81-72.25-48.2311.23126.61-36.4153.8724.54-7.59-40.16-138.0010.34-122.25-82.13612.7447.73-159.97-82.16-41.56-122.04-630.07-250.37-610.47
Surprise----------------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours----------------------

Key Statistics & Ratios

Market Cap57.33B
Enterprise Value30.26B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.32
Price / Book1.32
Revenue (TTM)8.43B
Gross Profit (TTM)6.36B
EBITDA1.64B
Profit Margin16.01%
Operating Margin13.06%
Return on Equity704.87%
Return on Assets1.36%
Shares Outstanding8.07M
Shares Float4.60M
Beta1.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20141×
25.00Dec 29, 2014

Stock Splits

  • Jul 11, 20182:1